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Abstract
Seroprevalence data of human herpesviruses (HHVs) are limited for sub-Saharan Africa. These are important to provide an
indication of potential burden of HHV-related disease, in particular in human immunodeficiency virus (HIV)-infected
individuals who are known to be at increased risk of these conditions in the Western world. In this cross-sectional study
among 405 HIV-infected and antiretroviral therapy naı¨ve individuals in rural South Africa the seroprevalence of HHVs was:
herpes simplex virus type 1 (HSV-1) (98%), herpes simplex virus type 2 (HSV-2) (87%), varicella zoster virus (VZV) (89%), and
100% for both Epstein-Barr virus (EBV) and cytomegalovirus (CMV). Independent factors associated with VZV seropositivity
were low educational status and having children. Lack of in-house access to drinking water was independently associated
with positive HSV-1 serostatus, whereas Shangaan ethnicity was associated with HSV-2 seropositivity. Increasing age was
associated with higher IgG titres to both EBV and CMV, whereas CD4 cell count was negatively associated with EBV and CMV
IgG titres. Moreover, IgG titres of HSV-1 and 2, VZV and CMV, and CMV and EBV were positively correlated. The high HHV
seroprevalence emphasises the importance of awareness of these viral infections in HIV-infected individuals in South Africa.
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Introduction
Herpes simplex virus type 1 (HSV-1) and 2 (HSV-2), varicella
zoster virus (VZV), Epstein-Barr virus (EBV), and cytomegalovirus
(CMV) are human herpesviruses (HHV) that are prevalent
worldwide. HHV Infections can lead to a variety of clinical
conditions that range in severity from cold sores and genital ulcers
(HSV), and chickenpox (VZV) to potentially sight-threatening (e.g.
CMV uveitis and HSV keratitis) or even life-threatening diseases
such as HSV encephalitis and EBV-associated malignancies [1–3].
Primary HHV infections, commonly acquired at young age, lead
to a life-long latent infection with intermittent reactivation
resulting in periodic asymptomatic or recrudescent disease. The
host immune system is pivotal to resolve lytic infections and to
inhibit HHV reactivation from latency. Consequently, reactivation
of HHV is much more frequent among immunocompromised
individuals including those infected with human immunodeficien-
cy virus (HIV) [4,5]. Also, HIV-infected individuals have an
increased risk of developing more severe HHV-related disease
[4,5]. Even after the introduction of antiretroviral therapy (ART),
HIV-infected individuals remain at risk of developing severe
HHV-related diseases as ART-induced recuperation of adaptive
immunity may result in vigorous anti-HHV cellular immune
responses. In the case of residual ocular CMV infection, restored
CMV immunity may lead to sight-threatening immune recovery
uveitis [6]. HHV infections clinically interact with HIV, contribute
substantially to hospitalization, morbidity and mortality and some
HHVs (e.g. HSV-2) may even facilitate HIV transmission [4,7,8].
This is of particular importance in sub-Saharan Africa where HIV
prevalence rates are at their highest. Despite the roll-out of ART
programmes in this region, ART coverage is still low [9]. Many
HIV-infected patients seek healthcare with considerably more
advanced immunodeficiency and may present with clinically
different HHV-related diseases compared to individuals in
resource-rich countries. In contrast to developed countries, where
HHV seroprevalence and occurrence of associated diseases are
well-documented, there is only scarce information available on the
seroprevalence and risk factors of HHV infections in sub-Saharan
Africa. This information is important to provide an indication of
the burden of HHV infections which is particularly relevant for
HIV-infected individuals who are known to be at increased risk for
development of HHV-induced disease due to reactivation.
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Material and Methods
Study setting and population
Study participants were recruited between September 2012 and
January 2013 at primary healthcare (PHC) facilities across the
Mopani District (Limpopo Province, South Africa), where the two
main ethnic groups are Sotho (46%) and Shangaan (44%) [10].
Participating PHC facilities were selected by ratio of population-
size of each of five sub-districts with a minimum of two PHC
facilities/sub-district. Within each sub-district, PHC facilities were
selected based on the number of patients on the ‘wellness, pre-
ART programme’, geographic location and size of the catchment
area. Individuals who had an indication to draw blood for
determination of CD4 count (CD4 T-cells/mm3 blood) were
eligible for this study. Criteria to participate were adult age (i.e. 18
years and older) and no prior ART exposure. Low educational
status and low financial income were defined as having no
education or primary school only, and persons with a government
grant as the main source of income, respectively. The study was
performed according to the tenets of the Helsinki Declaration,
approved unconditionally by the Human Research Ethics
Committee (Medical) of the University of the Witwatersrand,
Johannesburg, South Africa (reference number: M120546), and
written informed consent was obtained from all participants.
Study and laboratory procedures
Demographic and clinical data were collected upon inclusion
(Table 1). A whole blood sample was drawn and diagnostic CD4
counts were determined using the Cytomics FC 500 MPL
platform (Beckman Coulter). Serological analysis was performed
at the Laboratory of Viroscience at the Erasmus Medical Center in
Rotterdam, The Netherlands. HHV-specific serum IgG titres were
determined using Serion ELISA classic tests (Virion Serion) on the
Anthos-Labtec AR8001 platform (Anthos Labtec). ELISAs were
performed and data interpreted (i.e. seropositive, borderline or
seronegative) per manufacturer’s guidelines (Virion Serion).
Statistical analysis
Clinical and laboratory data were double-entered and validated
using EPI-INFO version 3.5.4 (Centers for Disease Control).
Description of study population and seroprevalence is done using
number with proportion and mean with standard deviation. To
identify factors associated with HHV-specific positive serostatus,
excluding persons with borderline ELISA results, univariate
analysis was performed using Chi-squared test, or Fisher’s Exact
test if appropriate, for categorical variables and Mann-Whitney
and Student T-test for continuous variables. Data are presented as
odds ratio (OR) with 95% confidence interval (CI), mean with
standard deviation (SD) or as median. To identify factors
independently associated with seropositive status variables with
p-values ,0.10 in univariate analysis, and age and gender as
potential confounders, were included in multivariate analysis using
logistic regression (forward Likelihood Ratio) with HHV seropos-
itivity as dichotomous measure of outcome. The potential
correlation of log2 HHV IgG titres with age and CD4 count
was analysed using Spearman’s correlation coefficient. Multiple
linear regression analysis was performed to determine potential
association of age and CD4 count, adjusting for gender and
ethnicity, with the log2 HHV titre as continuous measure of
outcome, providing assumptions for linear regression were met.
Statistical analyses were conducted using PASW Statistics and
p-values ,0.05 were considered statistically significant.
Results
Study population
The study population of 405 HIV-infected and ART-naı¨ve
adults consisted of 72 (18%) men and 333 (82%) women (Table 1).
The mean age was 37.9611.5 years. Men were significantly older
(mean age of 42 versus 37 years, p= 0.002), more often employed
(age-adjusted OR (aOR) = 4.5; 95% CI: 2.6–7.7, p,0.001), were
or had been married (aOR = 1.8; 95% CI: 1.0–3.1, p,0.05) and
had lower mean CD4 counts than women (306 vs. 398 cells/mm3;
p,0.001). Most participants had children (87%) and some had
limited access to in-house drinking water (6.2%) and latrine
(5.0%). Thirty (8%) participants were newly diagnosed for HIV
infection, 354 (87%) attended the ‘wellness, pre-ART programme’
and 21 (5%) individuals attended the clinic for baseline results
before ART initiation. Mean CD4 count was 3826226 CD4 T-
cells/mm3 and fifty percent of participants had CD4 counts #350
cells/mm3, which is the threshold in South Africa to initiate ART
[12].
Seroprevalence of HHVs
HHV seroprevalence was determined in 402 samples (three
were unavailable after transport); serum HHV ELISA data are
summarized in Table 2. Excluding borderline results, HHV
seroprevalence was very high: HSV-1 98% (95% CI: 96–99%);
HSV-2 87% (95% CI: 83–90%); VZV 89% (95% CI: 86–92%)
and 100% for both EBV and CMV. Seroprevalence was similar
between individuals with CD4 count below and above 350 cells/
mm3 for HSV-1 (98% vs. 97%; p = 0.33), HSV-2 (89% vs. 84%;
p = 0.17) and VZV (91% vs. 88%; p = 0.35). Neither HHV
seropositive status with CD4 count nor clinical HIV and HHV-
related clinical symptoms was associated at time of sampling. The
frequency of reported HHV-related clinical symptoms was low
and not associated with the respective HHV seropositive status.
History of chickenpox was reported by 72 (20%) of VZV
seropositive and 5 (12%) of VZV seronegative individuals
(p= 0.2) and herpes zoster by 50 (14%) and 4 (10%), respectively.
Among HSV-1 seropositive individuals a history of cold sores and
oral lesions was reported by 54 (15%) and 49 (14%) study
participants, respectively. HSV-1 seronegative individuals did not
report these diseases. Anogenital lesions were reported by 77
(24%) and 10 (20%) HSV-2 seropositive and seronegative study
participants, respectively.
Factors associated with positive HHV serostatus
Crude clinical and demographic factors associated with
individuals’ HHV seropositive vs. seronegative status for HSV-1,
HSV-2 and VZV are summarized in Table 3. The 100%
seroprevalence for EBV and CMV precluded calculation of such
factors. Adjusting for age and gender, lack of in-house access to
drinking water (aOR = 7.7; 95% CI: 1.8–33, p= 0.006) and
Shangaan ethnicity (aOR = 2.4; 95% CI: 1.2–4.5, p= 0.008) were
independently associated with positive HSV-1 and HSV-2
serostatus, respectively. Low educational status (aOR = 4.0; 95%
CI: 1.8–9.0, p= 0.01), having children (aOR = 2.2; 95% CI: 1.0–
4.9, p= 0.04) and a higher number of children in the household
(p value = 0.007) were independently associated with VZV
seropositivity, including adjustment for age and gender (data not
shown).
Next, we assayed potential correlations between HHV-specific
IgG titres and paired individual’s laboratory and clinical data
(Fig. 1). EBV and CMV IgG titres correlated significantly with age
and CD4 count. Increasing age was associated with higher EBV
(R2 = 0.05, p,0.001) and CMV IgG titres (R2 = 0.03, p= 0.0008)
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(Fig. 1A), whereas increasing CD4 count was negatively associated
with EBV (R2 =20.04, p= 0.0001) and CMV IgG titres
(R2 = 0.08, p,0.0001) (Fig 1B). There was no association of
CD4 count with HSV-1, HSV-2 and VZV IgG titre (see Fig. S1).
Higher HSV-1 IgG titres were detected among men (median
88 U/mL versus 66 U/mL in women; p= 0.001). Furthermore,
HSV-1 and HSV-2 (R2 = 0.03, p= 0.007), CMV and VZV
(R2 = 0.02, p= 0.013) and CMV and EBV (R2 = 0.18, p,0.0001)
IgG titres were positively correlated (Fig. 1C). No associations of
age, gender and ethnicity were observed between IgG titres for the
other HHVs.
Finally, multivariate analysis of determinants of HHV titre was
performed for age, gender, ethnicity and CD4 count. In
individuals with similar gender and ethnicity, there was an
association for every one year increase in age (0.17 unit) and every
cell reduction in CD4 count (20.25 unit) with CMV IgG titre.
Also, for every one year increase in age the EBV IgG titre was
associated with a 0.17 unit increase in titre in subjects comparable
in gender, ethnicity and CD4 count, whereas male gender was
associated with a decrease in HSV-1 IgG tire (20.17 unit; see
Table S1). No associations between HSV-2 and VZV IgG titres
and the aforementioned factors were observed.
Discussion
This study reports on the seroprevalence of HSV-1, HSV-2,
VZV, EBV and CMV among HIV-infected and ART-naı¨ve adults
in rural South Africa. We showed that HHV seroprevalence in this
population is very high. We identified several demographic factors
that were associated with a seropositive status for HSV-1, HSV-2
and VZV, but did not observe that clinical history of HHV
infection is predictive for the individual’s HHV serostatus.
We observed a relatively high seroprevalence of HHVs which
confirms observations in other studies addressing seroprevalence of
these viruses among HIV-infected individuals in Africa. Estimates
of HSV-1 and HSV-2 seroprevalence among adult HIV-infected
individuals vary across Africa, ranging from 65 to 90% in studies
from South Africa, Kenya, Lesotho and Tanzania [13–17]. High
prevalence rates (.85%) have also been reported for VZV, CMV
and EBV in HIV-infected adult individuals from several African
countries [13,14,18]. These infections may be acquired in early
childhood as illustrated by the 100% CMV seroprevalence among
a small cohort of city-dwelling HIV-infected children in Kenya
[19]. As such, a generally high seroprevalence of HHVs is manifest
among adults with HIV-infection across Africa. It should be noted
that we recruited a selected group of individuals in our study
(HIV-infected and ART-naı¨ve adults) and that our findings should
not be extrapolated to the general adult African population
including either HIV negative or HIV positive adults on ART
therapy. Since HIV-infection is associated with increased HHV
seroprevalence, it may be expected that seroprevalence of these
viruses in the general population would be lower as for example
shown for HSV and EBV [1,20].
We identified several factors associated with seropositive status
for 5 individual HHVs, but these should be interpreted with
caution as seroprevalence was very high, resulting in a relatively
small group of seronegative participants, and the effect of chance
associated with multiple comparison cannot be ruled out. In
addition, we like to point out that the use of prevalence odds ratio
instead of prevalence ratio may have resulted in an overestimation
of the observed associations; although there are pros and cons to
both measures of effect [21,22]. Low socioeconomic status -
represented here as lack of in-house access to drinking water - was
appeared to be associated with HSV-1 seropositivity. Shangaan
ethnicity was independently associated with HSV-2 seropositivity,
suggesting a higher HSV-2 infection rate among Shangaan
Table 1. Demographic characteristics of study participants
(n = 405).
Characteristic
Gender (male) 72 (18)
Age in years (mean (SD)) 38 (11)
Ethnicity
Shangaan 255 (65)
Sotho 138 (35)
Marital status
Never married 243 (60)
Married 129 (32)
Divorced or widowed 33 (8)
Has children 352 (87)
Individuals in household 5.1 (2.3)
Low educational status 192 (47)
Currently employed 103 (25)
Low financial income 184 (46)
In-house access to drinking water 25 (6.2)
In-house access to latrine 20 (5.0)
Keeps livestock 24 (5.9)
CD4 cell count in cells/mm3 (mean (SD)) 382 (226)
Clinical HIV-stagea
Stage 1 344 (85)
Stage 2 25 (6.0)
Stage 3 35 (9.0)
Stage 4 0 (0)
Data are presented as number (%) unless otherwise indicated. SD = standard
deviation; HIV = human immunodeficiency virus.
aClinical HIV-staging was done according to the WHO Clinical Staging of HIV/
AIDS [11].
doi:10.1371/journal.pone.0099243.t001
Table 2. Seroprevalence of human herpesviruses in HIV-infected individuals (n = 402).
HSV-1 HSV-2 VZV EBV CMV
Positive 361 (90) 316 (79) 353 (88) 400 (99.5) 402 (100)
Borderline 32 (8.0) 37 (9) 7 (1.7) 2 (0.5) 0 (0)
Negative 9 (2.2) 49 (12) 42 (10) 0 (0) 0 (0)
Data are presented as number (%). HSV = human simplex virus; VZV = varicella zoster virus; EBV = Epstein-Barr virus; CMV = cytomegalovirus.
doi:10.1371/journal.pone.0099243.t002
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Figure 1. Scatter plots of factors associated with human herpesvirus-specific serum IgG titres. Correlation between serum EBV and CMV
IgG titres and the individual’s (A) Age and (B) CD4 cell count. (C) Correlation between serum IgG titres of different human herpesviruses. Serum IgG
titres, presented as binary logarithmic PEI/ml values, were calculated based on corresponding reference sera from the Paul-Ehrlich Institute (Erlangen,
Germany). The Spearman correlation test was used for statistical analysis. HSV-1, herpes simplex virus 1; HSV-2, herpes simplex virus; VZV, varicella
zoster virus; EBV, Epstein-Barr virus and CMV, cytomegalovirus.
doi:10.1371/journal.pone.0099243.g001
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compared to Sotho. This potential association may be due to
different sexual risk behaviour between these ethnic groups
[unpublished data]. However, our study did not confirm
previously described associations of seropositivity for HSV-2 and
female gender, age, and other socioeconomic factors, but this may
be due to the high seroprevalence in our study population [23–27].
As reported earlier, VZV seropositive status associated indepen-
dently with age, low educational status, having children and
number of children, and number of individuals in the household
[28–32]. Notably, no association was observed between the
individual’s seropositive HHV status and a history of correspond-
ing HHV-specific clinical symptoms. This could be due to recall
bias as some infections would have occurred in early childhood
(e.g. varicella); other infections can have a subclinical course (e.g.
CMV, HSV) without ever presenting with clear symptoms or
being recognised by the individual. As such, based on the poor
predictive value, it would not be possible to identify individuals
with seropositive status, and thus at increased risk of HHV
reactivation and complications, based on clinical history taking.
We observed a moderate positive associations between EBV and
CMV IgG titres and age. As most individuals are infected with
HHV during childhood, increasing reactivation rates of the
respective HHVs during ageing and/or progress of HIV infection
may have attributed to this association [33,34]. Indeed, age-
related waning of cellular immunity and higher reactivation rates
of latent HHVs resulting in increased HHV-specific IgG and IgM
titres have been reported [33,35,36]. The negative association of
EBV and CMV IgG titres with CD4 count is in line with two
recent studies describing significant increase of activated HHV-
specific CD4 T-cells in HIV-infected individuals compared to HIV
naive individuals [37,38]. Decreasing CD4 count due to HIV
replication is associated with activation of CMV- and EBV-specific
CD4 T-cells as part of chronic immune activation, which may
subsequently stimulate humoral responses and produce higher IgG
titres in time.
The observed weak, though significant associations between
serum IgG levels of different HHVs suggest that risk factors of
reactivation leading to higher IgG titres partially overlap. The
associations between HSV-1 and HSV-2, and EBV and CMV IgG
titres may in part be attributed to the anatomic and cellular site
and corresponding immune responses involved in controlling viral
latency. Both HSV types establish latency in sensory neurons,
whereas lymphocytes are the main cell type of CMV (hematopoi-
etic progenitor cells) and EBV (B-cells) latency [39–41]. HIV
infection may inhibit specific immune cell types and mechanisms
that are commonly involved in controlling either latent neuro-
tropic (HSV-1 and HSV-2) and lymphotropic (EBV and CMV)
herpesviruses. Moreover, the positive association between age and
CD4 count with both EBV and CMV strengthen this assumption
that immunity to both viruses is entangled, which warrants further
studies [36]. However, contrary to our results, the observed
association in the latter study was between CMV and HSV-1 IgG
titres and was only significant in individuals ,45 years old. In
addition, CMV seropositivity, but not CMV IgG titres, has been
associated with increased VZV IgG titres [34]. Since all
individuals in our study cohort were CMV seropositive a similar
association analysis could not be performed.
There are several limitations to this study. First, PHC facilities
were not randomly selected within the five sub-districts in Mopani,
which may have resulted in some degree of bias in obtaining a
population estimate for the Mopani District. However, since PHC
facilities were sampled by ratio of sub-district’s population-size
with a minimum of two PHC facilities per sub-district and no
geographical variation was observed, we consider our study cohort
representative for HIV-infected individuals attending PHC
facilities in the Mopani district. Second, only individuals attending
PHC facilities were included, a population that may be different
for some demographic characteristics compared to those not
seeking healthcare. Generally, the latter group ultimately presents
with lower CD4 counts and higher risk of HHV-related disease
suggesting an under- rather than overestimate of seroprevalence.
Third, considerably more women than men were included in this
study, but statistical analyses were adjusted for gender. Fourth, the
use of self-reported clinical history of HHV infection may have
resulted in some degree of recall bias, especially since all
participants were adults. Finally, we did not include HHVs type
6 and 8 in our seroprevalence study; HHV-8 in particular is
associated with morbidity (Kaposi sarcoma) in HIV-infected
individuals.
HHV infections have currently limited priority and awareness
in the (pre-)ART programme of South Africa. The herein reported
high HHV seroprevalence and consequently high risk for HHV-
related diseases among HIV-infected individuals warrant in-
creased awareness among healthcare workers in rural South
Africa for early clinical signs of these conditions to initiate prompt
antiviral treatment: e.g. early diagnosis and treatment of herpes
zoster ophthalmicus to prevent corneal blindness [4,6]. In
conclusion, seroprevalence of HHVs in rural South Africa is very
high and recognition and awareness of HHV-related diseases is
warranted.
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